Clinical Trial: Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07521332) titled 'Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis' on March 31.

Brief Summary: The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Institute of Medical Sciences (AIMS) Hospital, Hyderabad, Pakistan, the trial will enroll eligible cirrhotic patients with portal hypertens...